Cognition Therapeutics Completes FDA End-of-Phase 2 Meeting For Zervimesine In Alzheimer’s

Refinitiv閱讀少於1分鐘

Cognition Therapeutics Inc CGTX:

COGNITION THERAPEUTICS COMPLETES END-OF-PHASE 2 MEETING WITH FDA FOR ZERVIMESINE (CT1812) IN ALZHEIMER’S DISEASE
COGNITION THERAPEUTICS INC - DISCUSSED PHASE 2 RESULTS AND PHASE 3 PLAN WITH FDA

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

登入或建立一個永久免費帳戶來閱讀此新聞